2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
5
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
1
Advanced Cancer
1
Interventions
Cyclophosphamide
2067
Radiotherapy
1990
Cisplatin
1856
Carboplatin
1560
Gemcitabine
1454
Paclitaxel
1320
Bevacizumab
1320
pembrolizumab
1238
Docetaxel
1227
Oxaliplatin
1184
Capecitabine
1178
Fluorouracil
1083
Dexamethasone
979
Magnetic Resonance Spectroscopy
971
Nivolumab
936
Rituximab
929
Drug Therapy
915
Surveys and Questionnaires
899
Doxorubicin
845
Etoposide
843
Radiosurgery
816
Blood Specimen Collection
816
Irinotecan
784
Cytarabine
743
fludarabine
726
Leucovorin
684
Surgical Procedures, Operative
640
Lenalidomide
618
Biopsy
594
fludarabine phosphate
569
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
tilsotolimod
×
Clear all
NCT04270864
2024-10-18
PRIMO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Terminated
25 enrolled
NCT04126876
2021-04-15
INTRIM
Amsterdam UMC, location VUmc
Phase 2
Recruiting
214 enrolled